Dr Reddys Laboratories Ltd Q1 FY2027 Concall Summary

Key Takeaways

• A quarter hit by one-offs, but the base business is running: Revenue fell 5.6% YoY as a ₹240 crore semaglutide provision and the absence of lenalidomide masked double-digit underlying growth across key markets.
• Semaglutide is the swing factor for FY27: A November supply restart would deliver 6–7 lakh pens in H2; management pegs the API fix at an 80–90% success rate, so the outcome is binary.
• Margin guidance held, but only by carving out semaglutide: The "neighbourhood of 20%" commitment excludes semaglutide and will be tested next quarter when that product contributes zero revenue.
• The US generics engine is grinding, not growing: Four years and ~100 launches later, the US business is still ~US\$950M, as price erosion consumes new product gains; double-digit growth this year relies on the base business, not the market.
• What to watch next quarter: Whether the semaglutide API testing succeeds by late September, the FDA's response to the Bachupally Form 483 (seven observations), and if the US base business can sustain its double-digit pace without the one large launch now expected in Q2.

Semaglutide: The Central Risk and Reward

• The provision: A ₹240 crore charge was booked for inventory and other costs tied to the API challenge; management stated no patient harm occurred from product already consumed.
• Root cause identified, fix underway: Activities have started at the site, with API testing expected to complete around the third week of September. Management estimates an 80–90% probability of success but cautioned it is not 100%.
• Supply restart and H2 volume: If testing succeeds, commercial supply resumes in November, delivering 6–7 lakh pens between November and March, down from the originally planned 10–11 lakh pens due to the four-month gap. Management believes demand for this volume is backed by orders.
• Canada deal intact: The Sandoz supply commitment still holds; management believes it can be met if supply resumes in November. A third competitor approved using Dr. Reddy's product is waiting for the operational issues to resolve.
• Brazil approval close: The earlier rejection was reversed; approval is expected in the next few weeks. Management sees no delays to applications in any market because specifications remain unchanged and the drug product quality is sound.
• PLI incentives paused: No PLI benefit was recorded in Q1; accounting will begin only once semaglutide supply resumes and minimum growth thresholds under the scheme are assessed.

Israeli: "The success rate is high, I don't know exactly the percentage. If I need to throw a number, it's somewhere between 80% to 90%. But there is a chance that it will fail, I just want to make sure, it's not 100%, but we feel relatively confident. Let's cross our fingers on that."

Base Business Performance

• Underlying growth was healthy: Excluding lenalidomide, the base business delivered double-digit growth across all key geographies, with Emerging Markets up 31% YoY and India up 17% YoY (15.5% organic).
• North America Generics fell 41% YoY on the lenalidomide comp, but the underlying base business grew double digits, aided by new launches. Management attributed the sequential decline to procurement and launch timing, not a fundamental issue.
• US generics: a treadmill, not an escalator: Over four years, ~90–100 product launches and the Mayne acquisition (~US\$100M incremental revenue) kept the business at ~US\$950M versus ~US\$1B in FY22. Management explained this is normal: new products compensate for price erosion, and the US generic market grows at best in single digits without upsides like lenalidomide.
• Europe was flat YoY and declined 3% sequentially, weighed by price erosion and the NRT operating model change, partially offset by new generic launches.
• PSAI declined 5% YoY and 10% sequentially on lower API volume uptake.
• NRT revenue decline is accounting, not economics: Post-integration (completed March 2026), rebates and discounts are now recognised net of revenue, with a corresponding SG&A reduction. The change is profit-neutral; EBITDA margins remain very healthy. Additional drag this quarter came from inventory cutoffs in some markets and the timing of a Brazil tender.

Margin Walk and Cost Structure

• Gross margin collapsed 1,039 bps YoY, driven by lower lenalidomide sales, the semaglutide API provision, and higher solvent costs from the Middle East conflict.
• SG&A rose 12% YoY, with 75–80% of the absolute increase (ex-R&D) attributed to adverse forex movements and elevated freight costs from the Middle East conflict. The remainder reflects annual increments and branded business investments.
• R&D spend declined 8% YoY on lower biosimilars development expenditure. Most R&D allocation is now directed at products targeting the 2034–2040 window, plus some licensing fees and remediation.
• Excluding one-offs, EBITDA margin was high-teens: Management stripped out semaglutide-related challenges and Middle East conflict impacts to arrive at this estimate.
• Productivity lever identified: Management plans to grow sales in double digits while holding associate cost growth to low single digits, creating a 10–12% gap. This is already visible when one-time items and war impacts are excluded, particularly in Emerging Markets (52% of the business) where revenue growth exceeds 15% against very low single-digit cost growth.
• Freight and solvent cost pressure is expected to persist at current elevated levels at least through December, as long as the Middle East conflict continues.

Israeli: "Still I maintain what we discussed a few weeks ago, that we are in the neighbourhood of the 20% and likely to stay. And that's what we are saying we will do including the next quarter, which will not be with semaglutide, so that's still the case to be in the neighbourhood of the 20%."

Pipeline and Regulatory Milestones

• Abatacept BLA on track, with a caveat: No queries have been received from the FDA as of the call date; the goal date remains December 2026. The product was filed only from the Bachupally site, not from a CMO. Management stated "we should get approval," but the recent Form 483 with seven observations at that same facility introduces uncertainty.
• Bachupally Form 483: The USFDA completed a Pre-License Inspection at the biologics facility in June 2026 and issued a Form 483 with seven observations. Management described them as "very different" from the five observations in the prior inspection and addressable; a response was submitted within the stipulated timeline. Management deflected on whether another inspection would be required.
• Abatacept launch sequencing: IV product upon approval (goal date December 2026); subcutaneous in the US around March/February 2028; subcutaneous in Europe around September–October 2028.
• Rituximab interchangeability will be granted, but US approval is delayed because the FDA inspection covered both abatacept and rituximab; once approved, partners can switch products.
• Denosumab BLA is from a partner; the partner has addressed FDA observations and resubmission discussions are ongoing.
• Bosutinib launched with 180-day exclusivity on the 400 mg strength; only two weeks of supply were in Q1. Nintedanib also launched in the US.
• One material US launch (tens of millions of dollars opportunity) is expected in the next couple of weeks, in Q2. The company is targeting 27 total US launches for the year.

Israeli: "To my opinion, we should get approval."

Geographic and Segment Highlights

• India innovation traction: Toripalimab, the in-licensed novel therapy for nasopharyngeal carcinoma, crossed the ₹100 crore club in under two years. Oral semaglutide was launched in India during the quarter.
• Canada semaglutide: Dr. Reddy's was first to secure approval and launch semaglutide for Type-2 diabetes. At launch, retailers assumed 60% generic share; management expects this to rise as confidence and supply grow, with the market becoming primarily generic.
• Zoliflodacin milestone: Thai FDA approval secured for this first-in-class gonorrhoea treatment, the first LMIC country to approve, six months after US FDA approval.

Capital Allocation and Strategic Moves

• CAPEX stepping down: FY27 capex is guided at ~₹1,800 crores, down from the earlier ~₹2,500–2,700 crores range, and expected to stay around that level going forward.
• Business development appetite is active: Management is engaged in deals across generics, innovation, and biosimilars; cash and balance sheet capacity will be deployed for inorganic opportunities.
• Biologics and peptide facilities are a cost drag today: Investments in CCM-5 for abatacept and peptide capacities (API, formulation, fill-finish) are hitting the P&L without offsetting revenue. These will turn profit-positive once the associated products launch. Management declined to quantify the current cost.
• Innoviva partnership: A deal to develop and commercialise XACDURO for hospital-acquired bacterial pneumonia across South and Central America, the Caribbean, Russia, and CIS countries.
• US tariffs viewed as noise: Management does not give the tariff threat much weight at this stage, calling it an opening for discussion. It noted that 25–30% of revenues are already manufactured by CMOs in the US.

Israeli: "On the tariff. We've been there last year. Obviously, it's a tweet. And between a Tweet and the reality, a lot of things likely to happen. As we speak, I don't see any reason to be concerned."

Guidance & Commitments

Key Metrics